Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

Sara A. Hurvitz, MD, associate professor, the David Geffen School of Medicine, the University of California, Los Angeles (UCLA), medical oncologist, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director, Santa Monica-UCLA Outpatient Oncology Practices, director, Breast Cancer Clinical Trials Program, UCLA, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial (NCT03529110) in HER2-positive breast cancer.

DESTINY-Breast03 produced some of the most riveting data in the HER2-positive breast cancer space in 2021, Hurvitz says. In this trial, randomized patients received either fam-trastuzumab deruxtecan-nxki (Enhertu) or ado-trastuzumab emtansine (T-DM1; Kadcyla) after prior treatment with trastuzumab (Herceptin) and a taxane, Hurvitz explains.

This phase 3 trial demonstrated a substantial improvement in progression-free survival with the use of trastuzumab deruxtecan vs T-DM1. Notably, trastuzumab deruxtecan benefited patients who had a history of brain metastases at baseline, Hurvitz concludes.